Cancer claims and specialty drugs drive stop-loss cost surge: QBE
The annual report, which draws on QBE’s proprietary claims data, found that neoplasms account for 36% of all stop-loss claim…
Blog
Blog
The annual report, which draws on QBE’s proprietary claims data, found that neoplasms account for 36% of all stop-loss claim…